Dan Brennan Joins Cowen’s Equity Research Team to Cover Life Science & Diagnostic Tools

Rhea-AI Summary

Cowen Inc. (NASDAQ:COWN) has expanded its equity research team with the addition of Dan Brennan, who specializes in life science & diagnostic tools. Brennan, previously at UBS, will contribute to Cowen's growing focus in this sector. Cowen boasts a robust research team of 58 senior analysts covering nearly 950 securities across various sectors, including healthcare and technology. The firm is known for its competitive healthcare research capabilities, consistently ranked among the best by Institutional Investor and Refinitiv.

Positive

• Dan Brennan's addition enhances Cowen's life science & diagnostic tools sector coverage.
• Cowen has a strong research network with 58 senior analysts covering approximately 950 securities.
• The firm's healthcare research is highly regarded, consistently ranked among the best.

Negative

• None.

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Dan Brennan has joined the Company’s equity research team to further expand the firm’s coverage of the life science & diagnostic tools sector. He will be based in New York, and will report to Robert Fagin, Cowen’s Head of Research.

“Cowen is committed to expanding its research efforts in the life science & diagnostic tools sector,” said Mr. Fagin. “We are thrilled to welcome Dan to Cowen and are confident that his wealth of experience and stellar reputation will be a valuable addition to this growing team.”

Cowen’s acclaimed research department consists of 58 senior analysts covering nearly 950 securities across multiple sectors, including health care, consumer, energy, sustainability and energy transition, technology media & telecom, capital goods & industrials, and Washington policy.

Prior to joining Cowen, Mr. Brennan was a Managing Director and senior analyst for life science & diagnostic tools at UBS Group, where he was also the health care team leader. Prior to UBS, he was a senior health care analyst at Columbus Circle Investors. Mr. Brennan also spent 12 years at Morgan Stanley, where he served as the health care sector equity sales specialist and later as life science & diagnostic tools analyst in the company’s research division. Mr. Brennan holds a B.A. in economics from Georgetown University and an M.B.A. from Harvard University. Mr. Brennan is a CFA® charterholder.

About Cowen Health Care Research

• With 18 senior analysts, Cowen has one of the largest health care research footprints on Wall Street.
• The team includes two analysts in Cowen’s Washington Research Group focused exclusively on health care policy. This effort complements, and is integrated with, the firm’s fundamental analysis.
• Cowen’s health care analysts are consistently ranked among the best in third-party polls such as Institutional Investor magazine’s All-America Research Team and the Refinitiv StarMine Analyst Awards.
• The team boasts a long tradition of collaboration and thought leadership. Marquee publications such as Cowen’s Biotech Quarterly, Therapeutics Categories, and the annual drug pricing survey have been widely read, and published consistently, for more than 25 years. Other major publications include Pharmaceutical Industry Pulse, Specialty Pharmaceutical Industry Pulse, and Life Science Tool Kit.
• The research team also publishes numerous studies under Cowen’s flagship Ahead of the Curve® Series banner. Recent reports have included in-depth explorations of immune-oncology, gene therapy, and Respiratory Syncytial Virus (RSV).
• The Company hosts some of the longest-running and best-attended events in the sector, including Cowen’s Health Care Conference (now in its 42^nd year); the Therapeutics Conference (now in its 24^th year); the MedTools Conference (now in its 10^th year); and the FutureHealth Conference (now in its 7^th year). Cowen also hosts numerous targeted events, which this year include Cowen’s Gene Therapy Summit, Oncology Innovation Summit, and Psychedelics & Novel Mechanisms in Neuropsychiatry Summit.

About Cowen Inc.
Cowen Inc. (“Cowen” or the “Company”) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division. The Company’s broker dealer division offers investment banking services, equity research, sales and trading, prime brokerage, global clearing and commission management services. Cowen’s investment management division builds on Cowen’s core insights by developing differentiated, actively managed investment strategies that seek to meet the dynamic needs of our clients. Founded in 1918, the firm is headquartered in New York and has offices worldwide. Learn more at Cowen.com.

© 2021, COWEN INC., ALL RIGHTS RESERVED. COWEN AND COMPANY, LLC: MEMBER FINRA, NYSE AND SIPC 

MEDIA CONTACT
Gagnier Communications
Dan Gagnier
dg@gagnierfc.com
646 569 5897

FAQ

What is Cowen's focus with the new hire of Dan Brennan?

Cowen's focus is to expand its equity research in the life science & diagnostic tools sector with Dan Brennan's expertise.

How many analysts does Cowen have in its research team?

Cowen has 58 senior analysts in its research department.

What sectors does Cowen cover with its research?

Cowen covers multiple sectors, including health care, consumer, technology, and more.

What prior experience does Dan Brennan have before joining Cowen?

Dan Brennan was a Managing Director at UBS and has previous experience at Columbus Circle Investors and Morgan Stanley.

How is Cowen's healthcare research recognized?

Cowen's healthcare research is consistently ranked among the best in third-party polls like Institutional Investor and Refinitiv.